Santa Monica, CA, May 20, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that Dr. Jerome B. Zeldis agreed to re-join the Company as an Independent Director, […]
Financial
BioCardia Reports 2019 First Quarter Financial Results and Business Highlights
SAN CARLOS, Calif., May 20, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2019 and filed its quarterly report on Form 10-Q for the three months ended March […]
Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million
VANCOUVER, May 16, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ:NVCN)(TSX:NVCN) announced today that it has closed its previously announced private placement (the “Private Placement”) of (i) a 15% original issue discount convertible debenture (the “Debenture”) with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and […]
Medical Device Industry Veteran Rob Abrams to Join Evolve Team
SOLANA BEACH, Calif.–(BUSINESS WIRE)–Evolve Medtech Partners, a medical device development company and incubator, is pleased to announce that Rob Abrams has joined the company as a partner. “We’ve had the pleasure of getting to know Rob over a number of years and recognize him as an exceptionally talented executive with an impressive […]
Shockwave Appoints Keith D. Dawkins M.D. as Chief Medical Officer
SANTA CLARA, Calif., May 15, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Keith D. Dawkins, M.D. as Chief Medical Officer. “Given the challenges associated […]
InspireMD Announces First Quarter 2019 Financial Results
TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the first quarter ending March 31, 2019. First Quarter 2019 and […]
Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million
VANCOUVER, May 14, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has entered into an agreement to sell to […]
John Fletcher Named Strategic Advisor to Micro Medical Solutions
WILMINGTON, Mass., May 14, 2019 /PRNewswire/ — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, announced today that John Fletcher has signed on as a strategic advisor to the company’s senior management. Mr. Fletcher is the founder and leader of healthcare consulting and […]
Ra Medical Systems Reports First Quarter 2019 Financial Results
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2019 and provides a business update. Recent Operational Highlights Submitted an Investigational Device Exemption (IDE) to the […]
Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO® (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under […]



